Results 241 to 250 of about 277,119 (298)

EZH2 confers lenvatinib resistance in hepatocellular carcinoma by suppressing ACSL1-Mediated ferroptosis. [PDF]

BMC Cancer
Zhang Y, Lin Y, Cai H, Zhou T.
europepmc   +1 more source

Caffeine improves diethylnitrosamine-induced hepatocellular carcinoma by inhibiting cAMP/PKA/CREB signaling in rats. [PDF]

Biochem Biophys Rep
Shan L, Wang C, Fang X, Zhang Z, Dai S, Liu J.   +5 more
europepmc   +1 more source

Role of the Wnt/β-catenin signaling pathway in the development of HCC. [PDF]

Front Immunol
Lin B, Li M.
europepmc   +1 more source

Two-way increased-risk associations between hepatobiliary cancers and other malignancies: a population-based study. [PDF]

Hepat Oncol
Deng H, Gong X, Wang M, Zhang Q, Li F, Wu X, Zhang Q.   +6 more
europepmc   +1 more source

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

International Journal of Cancer, EarlyView.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna Thomas, Michael W. M. Kühn, Michael Lübbert   +7 more
wiley   +1 more source

Dual regulatory role of natural killer T cells during development of hepatocellular carcinoma. [PDF]

Commun Biol
Papanastasatou M, Gioulbasani M, Nakou E, Galaras A, Rubio-Tomás T, Talianidis I, Eliopoulos AG, Hatzis P, Verykokakis M.   +8 more
europepmc   +1 more source

Targeting aerobic glycolysis combats tyrosine kinase inhibitor resistance of hepatocellular carcinoma

International Journal of Cancer, EarlyView.
Abstract Hepatocellular carcinoma (HCC) represents the predominant form of primary liver cancer and is frequently identified at a late stage, necessitating systemic therapy. However, resistance to first‐line tyrosine kinase inhibitor therapies, such as sorafenib and lenvatinib, remains a significant clinical challenge.
Longtao Zhao, Junjie Cheng, Yiming Zheng, Jing Wu, Jia Fan, Haixiang Sun, Chao Gao   +6 more
wiley   +1 more source

Advances and challenges in immunotherapy and molecular imaging for hepatocellular carcinoma. [PDF]

Discov Oncol
Haibin T.
europepmc   +1 more source

Genetic variants underlying precancerous conditions of hepatocellular carcinoma

International Journal of Cancer, EarlyView.
Abstract Hepatocellular carcinoma (HCC) is the most common form of liver cancer, accounting for 80% of cases worldwide. While chronic hepatitis B and C infections remain primary risk factors, emerging evidence highlights the increasing contributions of metabolic dysfunction‐associated steatotic liver disease (MASLD) and alcohol‐associated liver disease
Jonathan Jaime G. Guerrero, Paolo C. Encarnacion, Mark Angelo S. del Rosario, Matthew Aldren S. Ora, Jiayan Zhou, Kin Israel Notarte, Wan‐Chun Li, Ching‐Wen Chang   +7 more
wiley   +1 more source

Integrative Single-Cell and Bulk Transcriptomic Analysis Identifies Macrophage-Related Gene Signatures Predictive of Hepatocellular Carcinoma in Cirrhosis. [PDF]

Genes (Basel)
Zhang Z, Zeng C, Yong X, Zhou W, Xie Y, Shu J.   +5 more
europepmc   +1 more source